The Team

PD-MitoQUANT involves 14 different partners from 9 countries. The project brings together a multi-disciplinary team with expertise in mitochondrial biology, disease models, systems modelling, bioinformatics, preclinical research/imaging and patient engagement.

Project Coordinator

Jochen Prehn RCSI

Professor Jochen Prehn is the Coordinator of the PD-MitoQUANT project. He is Director of the Centre of Systems Medicine at the RCSI (Royal College of Surgeons Ireland) and Chair of the RCSI Department of Physiology and Medical Physics. Prof Prehn has acted as coordinator and/or Principal Investigator for a number of national and international research projects including APO-DECIDE, OXYSENSE and APO-SYS. Prof Prehn is an expert in neurodegeneration, medical systems biology and cell survival and death signalling, and has more than 200 peer-reviewed publications including publications in J Neurosci, Nature Genetics, Proc Natl Acad Sci USA, EMBO J and J Cell Biol (Google Scholar: h-index 68; >15,000 cited).

Project Leader

Ian Reynolds Teva

Dr. Ian Reynolds is the Project Leader, serving as a consultant on behalf of Teva Pharmaceutical Industries, sharing overall leadership with the Coordinator. Throughout his career, Dr. Reynolds held senior positions at diverse pharmaceutical companies and academia, all specializing in central nervous system drug discovery. Dr. Reynolds is a Fox Advisor at the Michael J. Fox Foundation (2012 – present), a member of the Scientific Advisory Board of the Parkinson’s Foundation (2004 – present), and a member of the Independent Review Committee of Target ALS. He is also an active member of the NIH/NINDS Study Section on Neurological Sciences and Disorders (NSD B).

Scientific Co-Leaders

Dr. Tina Stummann and Dr. Olga Corti are Scientific Co-Leaders, focusing on orchestration and integration of the scientific work of the project.

Dr. Tina Stummann is a Senior Research Scientist in the Department of Proteinopathy at Lundbeck A/S. She leads Lundbeck’s stem cell group, with extensive experience in establishing models based on neuronal differentiation of pluripotent stem cells, in vitro tau and αSyn models in iPSC neurons and functional electrophysiological endpoints in αSyn seeded primary neurons. She is a key driver of Lundbeck’s knowledge platform on mitochondrial dysfunction in Parkinson’s and Alzheimer’s disease.

Olga Corti

Dr. Olga Corti is a Research Director at Institut National de la Santé et Recherche Médicale and joint head of the team “Molecular Physiopathology of Parkinson’s disease” at the Institut du Cerveau et de la Moelle Epinière. She is expert in the functional analysis of protein products of Parkinson’s genes, with a focus on mechanisms of mitochondrial quality control. Dr. Corti has acted as Principal Investigator or coordinator in projects funded by the French National Research Agency, France Parkinson, Fondation de France, Michael J Fox Foundation and the European Union, such as MeFoPa and ERA-Net NEURON-REPark.